messag two senior departur month big ignor
take increment conserv approach head year annual
guid trim estim maintain neutral rate
pt continu question strateg rational dual-prong
medic strategi would refer investor back note
thorough discuss believ divis would better
bottom line morn announc ceo medic
segment jon giacomin would leav compani mid-august ceo role
privately-held compani compani also announc appoint stephen
current presid compani cardin at-hom solut busi
becom ceo medic segment surpris appoint mr
appear sales-ori background seem like
strateg fit ceo role given varieti previous disclos global manufactur
issu plagu compani year would also note second
senior departur month roughli two week ago compani disclos cfo
jorg gomez depart take cfo role despit
reaffirm midpoint guidanc believ departur rais uncertainti
level head compani initi guidanc report quarterli result
august accordingli take slightli conserv approach model
head guid see longer term continu question dual-prong
pharmaceut medic strategi believ best path forward compani
sharehold would separ two busi
trim estim trim estim reflect heighten
level uncertainti around medic segment given recent manag turnov
revis adjust ep estim vs previous
lower estim primarili driven conserv assumpt around
revenu growth oper margin compani medic segment believ
manag may take opportun reinvest resolv key
issu linger part busi estim adjust
ep remain unchang set report result offer initi
guidanc august
continu believ chang strategy/restructur inevit discuss
previou note believ medic segment continu present
challeng compani investor patienc grown thin view problem
medic divis opaqu outsid manag core area expertis
cardin investor would benefit break-up two divis believ
appetit marketplac under-perform medic technolog asset
potenti use cash flow exist busi make improv
strengthen portfolio acquisit
valuat risk maintain neutral rate price target base
share eventu trade ebitda vs previou target multipl
slightli higher multipl driven recent improv perform
peer group cardin current trade ebitda histor
averag suppli chain averag believ discount
warrant given fundament issu busi view biggest risk
downsid increas gener deflat lower brand inflat either case
compani profit would like suffer addit on-going opioid litig continu
risk downsid potenti magnitud time fine unknown
believ risk upsid compani gener better-than-expect result
medic segment
page analyst certif import disclosur
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst research associ receiv compens base upon variou factor includ qualiti research investor client
feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic
inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori cardin inc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
